NS-089/NCNP-02

Phase 2Small molecule

NS Pharma

NS-089/NCNP-02 is one of 26 small molecule programs targeting Duchenne Muscular Dystrophy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Duchenne Muscular DystrophyActive, not recruiting

DMDCompleted

Duchenne Muscular DystrophyPhase 2

Active, not recruiting

DMDPhase 2

Completed

Competition

Competitive Landscape

40 competitors in Duchenne Muscular Dystrophy

#DrugCompanyPhaseTrials

Isordil

AstraZeneca

Approved

—2

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 3

Coreg

Akero Therapeutics

Approved

1 4

Rapamune

PPrism Pharmaceuticals

Approved

1 5

Advil

Garamycin

Rifadin

1 8

Duvyzat

Italfarmaco

Phase 3

2 9

Vyondys 53

Sarepta Therapeutics

Approved

2 10

Agamree

CCatalyst Pharmaceuticals, Inc.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Duchenne Muscular Dystrophy

NCT05996003

Q2 2027

Phase 2Active, not recruiting

DMD

NCT05135663

Clinical

Trials by Indication[1]

DMD2 trials

Exploratory Study of NS-089/NCNP-02 in DMD

Completed·NNational Center of Neurology and Psychiatry, Japan·Phase 1/2·NCT04129294·6 enrolled

Extension Study of NS-089/NCNP-02 in DMD

Active, not recruiting·NNippon Shinyaku Co., Ltd.·Phase 2·NCT05135663·6 enrolled

Duchenne Muscular Dystrophy1 trial

A Phase 2 Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NS-089/NCNP-02 in Boys With Duchenne Muscular Dystrophy (DMD)

Active, not recruiting· NS Pharma logo

NS Pharma·Phase 2·NCT05996003·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for NS-089/NCNP-02. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NS-089/NCNP-02 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NS-089/NCNP-02. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NS Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NS Pharma

NS-089/NCNP-02

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Trials by Indication[1]

DMD2 trials

Duchenne Muscular Dystrophy1 trial

References

Drug Info

Quick Facts

Related News